RxSight (RXST) announced that Shelley Thunen, the company’s CFO, is transitioning from her role. Thunen will remain with the company until the sooner of the appointment of her successor or January 31, 2026. Thunen has agreed to support the company as a consultant subsequent to the transition.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight Announces Executive Leadership Reorganization and New Appointments
- RxSight price target raised to $10 from $9 at Morgan Stanley
- RxSight Earnings Call: Mixed Signals Amid Growth and Challenges
- RxSight price target raised to $10 from $8 at Stifel
- RxSight price target raised to $9 from $8 at JPMorgan